Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
== Expression/Production systems == Different organisms may be used to express a gene's target protein, and the expression vector used will therefore have elements specific for use in the particular organism. The most commonly used organism for protein production is the bacterium Escherichia coli. However, not all proteins can be successfully expressed in E. coli, or be expressed with the correct form of post-translational modifications such as glycosylations, and other systems may therefore be used.
By choosing porous graphitic carbon as a stationary phase for liquid chromatography, even non derivatized glycans can be analyzed. Electrospray ionisation (ESI) is frequently used for this application.
The chelate effect increases as the number of chelate rings increases. For example, the complex [Ni(dien)2)]2+ is more stable than the complex [Ni(en)3)]2+; both complexes are octahedral with six nitrogen atoms around the nickel ion, but dien (diethylenetriamine, 1,4,7-triazaheptane) is a tridentate ligand and en is bidentate. The number of chelate rings is one less than the number of donor atoms in the ligand. EDTA (ethylenediaminetetracetic acid) has six donor atoms so it forms very strong complexes with five chelate rings. Ligands such as DTPA, which have eight donor atoms are used to form complexes with large metal ions such as lanthanide or actinide ions which usually form 8- or 9-coordinate complexes. 5-membered and 6-membered chelate rings give the most stable complexes. 4-membered rings are subject to internal strain because of the small inter-bond angle is the ring. The chelate effect is also reduced with 7- and 8- membered rings, because the larger rings are less rigid, so less entropy is lost in forming them.
Sources: en.wikipedia.org
=== 1950–60s === After the war, some of the inventions found new applications. The first transistor radio was released in 1954, and its manufacturing process made use of vacuum pumps. The first integrated circuit or "chip" came to the market at the end of the 1950s, and vacuum pumps again played an important role in their production. These early inventions were Edwards' first steps into the electronics and semiconductors industry, which is to this day the company's biggest market. Chips became increasingly small throughout the decades, increasing the importance of vacuum purity.
Medical applications of radio frequency (RF) energy, in the form of electromagnetic waves (radio waves) or electrical currents, have existed for over 125 years, and now include diathermy, hyperthermy treatment of cancer, electrosurgery scalpels used to cut and cauterize in operations, and radiofrequency ablation. Magnetic resonance imaging (MRI) uses radio frequency fields to generate images of the human body.
recognition site A specific motif or sequence, either of nucleotides in a nucleic acid molecule or of amino acids in a protein, that is "recognized" or identified by another protein in order to direct the protein's activity to a specific molecule or location. Recognition motifs may consist of a simple consecutive sequence within a single molecule or may involve multiple non-consecutive motifs, e.g. amino acids in separate parts of the same polypeptide which are brought into juxtaposition by the quaternary structure created during protein folding. Recognition sites often help to distinguish the nucleic acid or protein bearing the motif from other similar molecules and thereby identify it as a valid target for some biochemical activity, or to specify a locus or subregion within the larger macromolecule at which the activity is to occur. In this sense recognition sites are critical for properly localizing proteins to their biochemical targets. A protein's recognition site is often but not necessarily the same as its binding site or target site.
Sources: en.wikipedia.org
BIOCEV (Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University) is a joint research institute located in Vestec, Czech Republic. Established in 2015, it is operated by six institutes of the Czech Academy of Sciences (CAS) and two faculties of Charles University (Faculty of Science, Charles University and First Faculty of Medicine, Charles University). The center maintains collaborative ties with other institutions in the STAR cluster.
== Medical uses == Heartburn, acid indigestion, and sour stomach Treatment for gastric and duodenal ulcers Treatment for pathologic gastrointestinal hypersecretory conditions such as Zollinger–Ellison syndrome and multiple endocrine adenomas Treatment for gastroesophageal reflux disease (GERD) Treatment for esophagitis Part of a multidrug regimen for Helicobacter pylori eradication, although omeprazole may be somewhat more effective. Prevention of NSAID-induced peptic ulcers. Given to surgery patients before operations to reduce the risk of aspiration pneumonia.
24 May – Three crew members are injured in an engine room explosion aboard a ship berthed in Bluff. 26 May: Two of the New Zealand Government's "non-financial benefit sanctions" come into force: namely money management payment cards and community work experience activities. Heavy rain leads to flooding in Nelson and Westport. 27 May: Police Commissioner Richard Chambers overturns a directive from March 2025 instructing Police officers not to investigate "lower value" thefts, petrol drive-offs, shoplifting and fraud crimes. The Department of Conservation proposes axing 84 jobs to meet a Government directive for a 6.5 percent reduction in spending. 28 May: Health Minister Simeon Brown and Finance Minister Nicola Willis announce that the Government will invest in 126 additional beds and treatment spaces at Wellington Hospital. Anti-mining protesters picket ANZ Bank branches in Dunedin and other centres to protest against the bank's relationship with coal company Bathurst Resources, which has applied for a fast-track consent to mine the Denniston Plateau. 29 May: The Transport Accident Investigation Commission (TAIC) launches an explosion into a boiler room explosion aboard a ship berthed in Bluff that occurred on 24 May. A car crash causes a power outage and traffic disruption in Rotorua's Pukehangi suburb. 30 May: Police launch a review into how many cases of retail crime were filed after the rescindment of a controversial directive directing the Police not to investigate lower-value retail crimes.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.